The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Personalized Medicine for Cancer Market Research Report 2025
Synopsis
The global Personalized Medicine for Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Personalized Medicine for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalized Medicine for Cancer.
Report Scope
The Personalized Medicine for Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Personalized Medicine for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Personalized Medicine for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
GlaxoSmithKline
Novartis
Sanofi
Pfizer
Amgen
Merck
Bristol-Myers Squibb
Ariad Pharmaceuticals (Takeda)
Eli Lilly
Roche
Boehringer Ingelheim
Johnson and Johnson
Teva Pharmaceuticals
Segment by Type
Immunotherapy
Targeted Therapy
Chemotherapy
Hormone Therapy
Others
Segment by Application
Breast Cancer
Blood Cancer
Gastrointestinal Cancer
Prostate Cancer
Skin Cancer
Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Personalized Medicine for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Personalized Medicine for Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Personalized Medicine for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalized Medicine for Cancer.
Report Scope
The Personalized Medicine for Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Personalized Medicine for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Personalized Medicine for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
GlaxoSmithKline
Novartis
Sanofi
Pfizer
Amgen
Merck
Bristol-Myers Squibb
Ariad Pharmaceuticals (Takeda)
Eli Lilly
Roche
Boehringer Ingelheim
Johnson and Johnson
Teva Pharmaceuticals
Segment by Type
Immunotherapy
Targeted Therapy
Chemotherapy
Hormone Therapy
Others
Segment by Application
Breast Cancer
Blood Cancer
Gastrointestinal Cancer
Prostate Cancer
Skin Cancer
Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Personalized Medicine for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Medicine for Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immunotherapy
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Hormone Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Personalized Medicine for Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Blood Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Skin Cancer
1.3.7 Lung Cancer
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Personalized Medicine for Cancer Market Perspective (2019-2030)
2.2 Personalized Medicine for Cancer Growth Trends by Region
2.2.1 Global Personalized Medicine for Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Personalized Medicine for Cancer Historic Market Size by Region (2019-2024)
2.2.3 Personalized Medicine for Cancer Forecasted Market Size by Region (2025-2030)
2.3 Personalized Medicine for Cancer Market Dynamics
2.3.1 Personalized Medicine for Cancer Industry Trends
2.3.2 Personalized Medicine for Cancer Market Drivers
2.3.3 Personalized Medicine for Cancer Market Challenges
2.3.4 Personalized Medicine for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Medicine for Cancer Players by Revenue
3.1.1 Global Top Personalized Medicine for Cancer Players by Revenue (2019-2024)
3.1.2 Global Personalized Medicine for Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Personalized Medicine for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Personalized Medicine for Cancer Revenue
3.4 Global Personalized Medicine for Cancer Market Concentration Ratio
3.4.1 Global Personalized Medicine for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine for Cancer Revenue in 2023
3.5 Personalized Medicine for Cancer Key Players Head office and Area Served
3.6 Key Players Personalized Medicine for Cancer Product Solution and Service
3.7 Date of Enter into Personalized Medicine for Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalized Medicine for Cancer Breakdown Data by Type
4.1 Global Personalized Medicine for Cancer Historic Market Size by Type (2019-2024)
4.2 Global Personalized Medicine for Cancer Forecasted Market Size by Type (2025-2030)
5 Personalized Medicine for Cancer Breakdown Data by Application
5.1 Global Personalized Medicine for Cancer Historic Market Size by Application (2019-2024)
5.2 Global Personalized Medicine for Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Personalized Medicine for Cancer Market Size (2019-2030)
6.2 North America Personalized Medicine for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Personalized Medicine for Cancer Market Size by Country (2019-2024)
6.4 North America Personalized Medicine for Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Personalized Medicine for Cancer Market Size (2019-2030)
7.2 Europe Personalized Medicine for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Personalized Medicine for Cancer Market Size by Country (2019-2024)
7.4 Europe Personalized Medicine for Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine for Cancer Market Size (2019-2030)
8.2 Asia-Pacific Personalized Medicine for Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Personalized Medicine for Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Personalized Medicine for Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Personalized Medicine for Cancer Market Size (2019-2030)
9.2 Latin America Personalized Medicine for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Personalized Medicine for Cancer Market Size by Country (2019-2024)
9.4 Latin America Personalized Medicine for Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine for Cancer Market Size (2019-2030)
10.2 Middle East & Africa Personalized Medicine for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Personalized Medicine for Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Personalized Medicine for Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Personalized Medicine for Cancer Introduction
11.1.4 Bayer Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.1.5 Bayer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Personalized Medicine for Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Personalized Medicine for Cancer Introduction
11.3.4 Novartis Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Personalized Medicine for Cancer Introduction
11.4.4 Sanofi Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Personalized Medicine for Cancer Introduction
11.5.4 Pfizer Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Personalized Medicine for Cancer Introduction
11.6.4 Amgen Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.6.5 Amgen Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Personalized Medicine for Cancer Introduction
11.7.4 Merck Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Personalized Medicine for Cancer Introduction
11.8.4 Bristol-Myers Squibb Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Ariad Pharmaceuticals (Takeda)
11.9.1 Ariad Pharmaceuticals (Takeda) Company Detail
11.9.2 Ariad Pharmaceuticals (Takeda) Business Overview
11.9.3 Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Introduction
11.9.4 Ariad Pharmaceuticals (Takeda) Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.9.5 Ariad Pharmaceuticals (Takeda) Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Personalized Medicine for Cancer Introduction
11.10.4 Eli Lilly Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.10.5 Eli Lilly Recent Development
11.11 Roche
11.11.1 Roche Company Detail
11.11.2 Roche Business Overview
11.11.3 Roche Personalized Medicine for Cancer Introduction
11.11.4 Roche Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.11.5 Roche Recent Development
11.12 Boehringer Ingelheim
11.12.1 Boehringer Ingelheim Company Detail
11.12.2 Boehringer Ingelheim Business Overview
11.12.3 Boehringer Ingelheim Personalized Medicine for Cancer Introduction
11.12.4 Boehringer Ingelheim Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.12.5 Boehringer Ingelheim Recent Development
11.13 Johnson and Johnson
11.13.1 Johnson and Johnson Company Detail
11.13.2 Johnson and Johnson Business Overview
11.13.3 Johnson and Johnson Personalized Medicine for Cancer Introduction
11.13.4 Johnson and Johnson Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.13.5 Johnson and Johnson Recent Development
11.14 Teva Pharmaceuticals
11.14.1 Teva Pharmaceuticals Company Detail
11.14.2 Teva Pharmaceuticals Business Overview
11.14.3 Teva Pharmaceuticals Personalized Medicine for Cancer Introduction
11.14.4 Teva Pharmaceuticals Revenue in Personalized Medicine for Cancer Business (2019-2024)
11.14.5 Teva Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Personalized Medicine for Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Immunotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Hormone Therapy
Table 6. Key Players of Others
Table 7. Global Personalized Medicine for Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Personalized Medicine for Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Personalized Medicine for Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Personalized Medicine for Cancer Market Share by Region (2019-2024)
Table 11. Global Personalized Medicine for Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Personalized Medicine for Cancer Market Share by Region (2025-2030)
Table 13. Personalized Medicine for Cancer Market Trends
Table 14. Personalized Medicine for Cancer Market Drivers
Table 15. Personalized Medicine for Cancer Market Challenges
Table 16. Personalized Medicine for Cancer Market Restraints
Table 17. Global Personalized Medicine for Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Personalized Medicine for Cancer Market Share by Players (2019-2024)
Table 19. Global Top Personalized Medicine for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine for Cancer as of 2023)
Table 20. Ranking of Global Top Personalized Medicine for Cancer Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Personalized Medicine for Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Personalized Medicine for Cancer Product Solution and Service
Table 24. Date of Enter into Personalized Medicine for Cancer Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Personalized Medicine for Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Personalized Medicine for Cancer Revenue Market Share by Type (2019-2024)
Table 28. Global Personalized Medicine for Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Personalized Medicine for Cancer Revenue Market Share by Type (2025-2030)
Table 30. Global Personalized Medicine for Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Personalized Medicine for Cancer Revenue Market Share by Application (2019-2024)
Table 32. Global Personalized Medicine for Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Personalized Medicine for Cancer Revenue Market Share by Application (2025-2030)
Table 34. North America Personalized Medicine for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Personalized Medicine for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Personalized Medicine for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Personalized Medicine for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Personalized Medicine for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Personalized Medicine for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Personalized Medicine for Cancer Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Personalized Medicine for Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Personalized Medicine for Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Personalized Medicine for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Personalized Medicine for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Personalized Medicine for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Personalized Medicine for Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Personalized Medicine for Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Personalized Medicine for Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 49. Bayer Company Detail
Table 50. Bayer Business Overview
Table 51. Bayer Personalized Medicine for Cancer Product
Table 52. Bayer Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 53. Bayer Recent Development
Table 54. GlaxoSmithKline Company Detail
Table 55. GlaxoSmithKline Business Overview
Table 56. GlaxoSmithKline Personalized Medicine for Cancer Product
Table 57. GlaxoSmithKline Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 58. GlaxoSmithKline Recent Development
Table 59. Novartis Company Detail
Table 60. Novartis Business Overview
Table 61. Novartis Personalized Medicine for Cancer Product
Table 62. Novartis Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 63. Novartis Recent Development
Table 64. Sanofi Company Detail
Table 65. Sanofi Business Overview
Table 66. Sanofi Personalized Medicine for Cancer Product
Table 67. Sanofi Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 68. Sanofi Recent Development
Table 69. Pfizer Company Detail
Table 70. Pfizer Business Overview
Table 71. Pfizer Personalized Medicine for Cancer Product
Table 72. Pfizer Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 73. Pfizer Recent Development
Table 74. Amgen Company Detail
Table 75. Amgen Business Overview
Table 76. Amgen Personalized Medicine for Cancer Product
Table 77. Amgen Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 78. Amgen Recent Development
Table 79. Merck Company Detail
Table 80. Merck Business Overview
Table 81. Merck Personalized Medicine for Cancer Product
Table 82. Merck Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 83. Merck Recent Development
Table 84. Bristol-Myers Squibb Company Detail
Table 85. Bristol-Myers Squibb Business Overview
Table 86. Bristol-Myers Squibb Personalized Medicine for Cancer Product
Table 87. Bristol-Myers Squibb Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 88. Bristol-Myers Squibb Recent Development
Table 89. Ariad Pharmaceuticals (Takeda) Company Detail
Table 90. Ariad Pharmaceuticals (Takeda) Business Overview
Table 91. Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Product
Table 92. Ariad Pharmaceuticals (Takeda) Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 93. Ariad Pharmaceuticals (Takeda) Recent Development
Table 94. Eli Lilly Company Detail
Table 95. Eli Lilly Business Overview
Table 96. Eli Lilly Personalized Medicine for Cancer Product
Table 97. Eli Lilly Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 98. Eli Lilly Recent Development
Table 99. Roche Company Detail
Table 100. Roche Business Overview
Table 101. Roche Personalized Medicine for Cancer Product
Table 102. Roche Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 103. Roche Recent Development
Table 104. Boehringer Ingelheim Company Detail
Table 105. Boehringer Ingelheim Business Overview
Table 106. Boehringer Ingelheim Personalized Medicine for Cancer Product
Table 107. Boehringer Ingelheim Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 108. Boehringer Ingelheim Recent Development
Table 109. Johnson and Johnson Company Detail
Table 110. Johnson and Johnson Business Overview
Table 111. Johnson and Johnson Personalized Medicine for Cancer Product
Table 112. Johnson and Johnson Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 113. Johnson and Johnson Recent Development
Table 114. Teva Pharmaceuticals Company Detail
Table 115. Teva Pharmaceuticals Business Overview
Table 116. Teva Pharmaceuticals Personalized Medicine for Cancer Product
Table 117. Teva Pharmaceuticals Revenue in Personalized Medicine for Cancer Business (2019-2024) & (US$ Million)
Table 118. Teva Pharmaceuticals Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Personalized Medicine for Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Personalized Medicine for Cancer Market Share by Type: 2023 VS 2030
Figure 3. Immunotherapy Features
Figure 4. Targeted Therapy Features
Figure 5. Chemotherapy Features
Figure 6. Hormone Therapy Features
Figure 7. Others Features
Figure 8. Global Personalized Medicine for Cancer Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Personalized Medicine for Cancer Market Share by Application: 2023 VS 2030
Figure 10. Breast Cancer Case Studies
Figure 11. Blood Cancer Case Studies
Figure 12. Gastrointestinal Cancer Case Studies
Figure 13. Prostate Cancer Case Studies
Figure 14. Skin Cancer Case Studies
Figure 15. Lung Cancer Case Studies
Figure 16. Others Case Studies
Figure 17. Personalized Medicine for Cancer Report Years Considered
Figure 18. Global Personalized Medicine for Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 19. Global Personalized Medicine for Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 20. Global Personalized Medicine for Cancer Market Share by Region: 2023 VS 2030
Figure 21. Global Personalized Medicine for Cancer Market Share by Players in 2023
Figure 22. Global Top Personalized Medicine for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine for Cancer as of 2023)
Figure 23. The Top 10 and 5 Players Market Share by Personalized Medicine for Cancer Revenue in 2023
Figure 24. North America Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Personalized Medicine for Cancer Market Share by Country (2019-2030)
Figure 26. United States Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Canada Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe Personalized Medicine for Cancer Market Share by Country (2019-2030)
Figure 30. Germany Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific Personalized Medicine for Cancer Market Share by Region (2019-2030)
Figure 38. China Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Japan Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. South Korea Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. India Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Australia Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America Personalized Medicine for Cancer Market Share by Country (2019-2030)
Figure 46. Mexico Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Brazil Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Personalized Medicine for Cancer Market Share by Country (2019-2030)
Figure 50. Turkey Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Personalized Medicine for Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Bayer Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 53. GlaxoSmithKline Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 54. Novartis Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 55. Sanofi Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 56. Pfizer Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 57. Amgen Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 58. Merck Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 60. Ariad Pharmaceuticals (Takeda) Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 61. Eli Lilly Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 62. Roche Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 63. Boehringer Ingelheim Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 64. Johnson and Johnson Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Personalized Medicine for Cancer Business (2019-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
